Compare Monster Beverage Corp (MNST) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Monster Beverage Corp trades at $44.52 (market cap $84.85B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Monster Beverage Corp is far larger — about 17.4× Travere Therapeutics Inc. Common Stock's market cap, and Monster Beverage Corp is more actively traded (7,847,331 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MNST | TVTX | |
|---|---|---|
Market Cap | $84.85B | $4.88B |
Volume | 7,847,331 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $67.52 |
52-Week Low | $33.16 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $83.14B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $44.22, up 1.05% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust fundamentals including 55.55% gross margin and 23.08% net margin. Recent news highlights international growth, a debt-free balance sheet, and a 1:2 stock split effective August 2026.
Outlook remains positive with analyst consensus target of $98.22 implying significant upside, supported by international expansion and high profitability. Key risks include valuation multiples above industry averages and regulatory challenges in markets like India. The stock's growth trajectory is solid, but investors should weigh rich valuations against execution risks.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
